Exactly how many people have ADHD as number revealed for first time
ADHD is a neuro-developmental disorder and people with the condition may have trouble concentrating or sitting still. Other symptoms include being easily distracted, forgetfulness, finding it hard to follow instructions or organise time, and making impulsive decisions.
According to NHS England, a total of 2,498,000 people may have ADHD, including those without a diagnosis. Of this number, an estimated 741,000 are children and young people aged five to 24.
READ MORE: Police welcome 20-year sentence for predator who plotted with mum to rape girl
READ MORE: Barber catapulted rocks at rioters as he tried to defend Hanley mosque
The figures were developed using estimates from the National Institute for Health and Care Excellence (Nice), which suggests that around 3-4% of adults and 5% of children and young people have ADHD .
While ADHD is not usually diagnosed in children under five – as some traits can be part of typical development – prevalence in youngsters aged four and under have been calculated to give an insight into how many may go on to be diagnosed in the future.
Some 147,000 under-fives are likely to have ADHD , according to the NHS estimates. The figures also suggest that more than half a million people (549,000) in England were waiting for an ADHD assessment at the end of March 2025. This is up from 416,000 a year earlier at the end of March 2024.
Of the 549,000 likely to be waiting for ADHD assessment in March this year, some 304,000 had been waiting at least a year while 144,000 had been waiting at least two years. More than two-thirds (382,000) were aged between five and 24.
Louise Ansari, chief executive at Healthwatch England, said the figures are 'a first step in understanding the scale of demand for ADHD care'.
'Our new research highlights that many people with ADHD may simply be going without support,' she added. 'Long waits for assessments are one of the reasons people who show ADHD traits don't seek help, while those waiting for an assessment struggle to navigate the long waits.
'While we welcome today's publication, however, there is a way to go to ensure data is comprehensive and robust. A move to official waiting list data in the longer term would give a clearer picture of waiting times, including who is experiencing the longest waits and why.'
Estimates of how many adults in England are likely to be waiting for ADHD assessments is available dating back to 2019. They show the the number of people aged 25 and over who were waiting at the end of March was 165,000, more than 10 times the pre-pandemic figure of 16,000 at the end of December 2019.
Comparable data for children and young adults is available only for the most recent 12 months and shows the number rose from an estimated 285,000 at the end of March 2024 to 384,000 at the end of March this year.
Pippa Sargent, chief executive of The Brain Charity, said: 'It's a hugely positive step that more people are coming forward for ADHD assessments. This shows increasing awareness, self-advocacy and a shift in how society understands neurodiversity.
'It is important to remember that, despite its challenges, the condition brings with it many strengths that should be celebrated.
'But with up to 549,000 people now waiting, the scale of unmet need is alarming. Without urgent investment in diagnostic services and ongoing support, too many are being left to struggle alone.'
An NHS spokesperson said: 'Patients are waiting too long for an ADHD assessment and diagnosis and that's why the NHS launched an independent taskforce to investigate the challenges facing services and help them manage the rising numbers of referrals, with support from across society.
'The ADHD taskforce will assess these important new figures and the best available evidence to inform its recommendations, bringing together those with lived experience and experts across a range of sectors to help find long-term solutions for patients.'
Get daily headlines and breaking news emailed to you - it's FREE
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
10 hours ago
- Medscape
Early Puberty Onset Linked to Higher Mental Health Risk
TOPLINE: Patients diagnosed with central precocious puberty (CPP) — a condition in which physical changes related to pubertal development occur earlier than usual — had a nearly 50% elevated risk of developing psychiatric disorders, including depression and anxiety, and the incidence of both depression and attention-deficit/hyperactivity disorder (ADHD) remained persistently elevated for years after diagnosis. METHODOLOGY: Researchers in Germany conducted a population-based, retrospective cohort study using health insurance data (from January 2010 to June 2023) to evaluate the association between idiopathic CPP and the development of psychiatric disorders. They included 1094 patients with idiopathic CPP (91.3% girls) and individually matched them with 5448 control individuals without the condition (matched for sex, birth year interval, insurance period, and obesity); participants had continuous insurance coverage for at least 2 years during the study period. The exposure of interest was a diagnosis of CPP, and psychiatric outcomes evaluated included depression, anxiety disorders, oppositional defiant and conduct disorders, ADHD, self-harm behaviours, and substance use disorders. TAKEAWAY: Patients with CPP had a higher risk for any mental disorder than their matched control individuals (adjusted risk ratio [aRR], 1.48; 95% CI, 1.31-1.67). They also showed a higher risk for depression (aRR, 1.73; 95% CI, 1.37-2.20), anxiety disorders (aRR, 1.45; 95% CI, 1.16-1.82), oppositional defiant and conduct disorders (aRR, 1.76; 95% CI, 1.39-2.23), and ADHD (aRR, 1.53; 95% CI, 1.27-1.86) than matched control individuals. Temporal trends showed that incidence rates of oppositional defiant and conduct disorders were elevated even before the diagnosis of CPP; however, rates of depression and ADHD remained persistently high for up to 8 years after the initial diagnosis. IN PRACTICE: "Caretakers of patients with CPP should actively explore psychological symptoms and facilitate early intervention to influence lifetime trajectories of this vulnerable patient population positively. Because our findings indicate long-term sequelae of CPP on mental health, caretakers should be vigilant even after normalization of pubertal development," the authors wrote. SOURCE: This study was led by Lars Dinkelbach, MD, University Hospital Essen, University of Duisburg-Essen, Essen, Germany. It was published online on June 23, 2025, in JAMA Network Open. LIMITATIONS: This study relied on physician-reported diagnoses in a population-based setting and on routine health insurance data, which limited its ability to control for confounding variables. The precision of age-related analyses reduced due to data-anonymity policies of the insurance data. The small number of cases with self-harming behaviours or substance use disorders limited the ability to conclude any association. DISCLOSURES: This study was financially supported by a fellowship of the University Medicine Essen Clinician Scientist Academy, which was supported by the German Research Foundation and non-financially supported by the Gesellschaft für Wirtschaftlichkeit und Qualität bei Krankenkassen Service Plus AG. One author reported receiving grants from Gemeinsamer Bundesausschuss outside the submitted work. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Medscape
12 hours ago
- Medscape
Telehealth vs In-Person ADHD Prescribing: Which is Safest?
TOPLINE: Prescribing stimulants for teens and adults with attention-deficit/hyperactivity disorder (ADHD) via telehealth was not associated with increased risk for substance use disorder (SUD) compared with in-person prescribing, a new study suggested. However, receiving an initial stimulant prescription via telehealth was linked to a sixfold higher risk for stimulant use disorder (stimUD). METHODOLOGY: Researchers analyzed electronic health record data for nearly 8000 US patients with ADHD from 2020-2023. Participants were aged ≥ 12 years (52% > 26 years, 25% 18-25 years, and 23% 12-17 years), had received initial stimulant prescriptions during the study, and did not have a non-nicotine SUD diagnosis at baseline. 26 years, 25% 18-25 years, and 23% 12-17 years), had received initial stimulant prescriptions during the study, and did not have a non-nicotine SUD diagnosis at baseline. Outcomes were the development of stimUD or non-nicotine SUD, defined as meeting one of the three criteria: a diagnostic billing code, a positive response on patient-reported outcome measures, or receipt of medications approved by the FDA for SUD treatment. Patients were grouped on the basis of whether their relationship with the prescriber was exclusively via telehealth (n = 720) or included in-person contact (n = 7224); and whether the stimulant prescription was issued via telehealth (n = 3981) or in-person (n = 3963). Covariates included psychiatric comorbidities, demographic factors, and characteristics of clinical care. TAKEAWAY: After adjusting for covariates, SUD risk was not significantly higher among patients with a telehealth-exclusive relationship with their prescriber (adjusted odds ratio [aOR], 0.9; P = .35) or a stimUD (aOR, 1.3; P =.72) than among those with in-person relationships. relationship with their prescriber (adjusted odds ratio [aOR], 0.9; P = .35) or a stimUD (aOR, 1.3; P =.72) than among those with in-person relationships. Receiving an initial stimulant prescription via telehealth was associated with a significantly higher risk for stimUD (aOR, 6.2; P = .02) but not SUD (aOR, 1.2; P = .23) than receiving that via in-person. For patients aged 26 years or older, receiving initial stimulant prescriptions via telehealth was associated with a significantly higher risk for subsequent SUD (aOR, 1.5; P = .03) than receiving that via in-person. This association was not significant in younger age groups. IN PRACTICE: 'Our study suggests that, generally, telehealth-based relationships — which make healthcare more accessible — can be safe and don't increase the risk of substance use disorder,' lead study investigator Vinod Rao, MD, PhD , Massachusetts General Hospital, Boston, said in a press release. However, the findings, 'particularly for stimUD, require replication in other healthcare settings,' the investigators wrote. SOURCE: This study was published online on June 11 in The American Journal of Psychiatry. LIMITATIONS: Limitations included a reliance on administrative claims data, which captured filled prescriptions but not actual medication use, potentially introducing exposure misclassification. Diagnoses of SUDs were according to coded claims rather than clinical assessments, which may have led to underreporting or misclassification. The analysis was also limited to commercially insured participants, reducing the generalizability of the findings. Additionally, race and ethnicity data were incomplete, and long-term outcomes beyond 12 months were not assessed. DISCLOSURES: This study was funded by research awards from the FDA and the National Institute on Drug Abuse. Two investigators reported receiving research funding from the National Institutes of Health and private foundations, receiving support for clinical program development from regional health organizations and foundations, holding consultancy or editorial roles with government, nonprofit, and academic entities, or having intellectual property interests related to pharmaceutical and digital therapeutics collaborations. The other five investigators reported no relevant financial relationships. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Associated Press
14 hours ago
- Associated Press
Swedish Study Finds Attention-Deficit/Hyperactivity Disorder (ADHD) Medications Linked With Safer Outcomes
NEW YORK, NY - June 30, 2025 ( NEWMEDIAWIRE ) - A major Swedish study of 247,420 individuals with attention-deficit/hyperactivity disorder (ADHD) has found that medication treatment is consistently linked to lower rates of self-harm, accidents, and criminal behavior. The research, in JAMA Psychiatry, shows that people with ADHD experience fewer such adverse events during periods on medication compared to periods off medication. As expected, as less severe cases of ADHD are diagnosed and treated with medication, the reduction in adverse events narrows. Dr. Ryan Sultan - Director of Integrative Psychiatry and a Columbia University Psychiatry Assistant Professor and internationally recognized ADHD expert – authored an invited commentary on the findings. 'When used appropriately, ADHD medications help patients not just feel better, but live safer, more productive lives,' said Dr. Sultan. He noted that this growing body of evidence underscores how effective ADHD treatment yields real-world benefits beyond symptom relief. As the population of individuals treated for ADHD has risen, the study found that the medication's effect on reducing adverse events was less for the newly diagnosed than the previously diagnosed. In Sweden, ADHD medication use roughly tripled among youth and rose more than fivefold among adults from 2006 to 2020. During this period, the medication's impact on outcomes like injuries and crime, while still significant, became less pronounced. 'As we diagnose and treat more people with ADHD - including adults and women with milder symptoms - it's expected that the average drop in severe outcomes like arrests or accidents will be smaller,' Dr. Sultan explained. 'That doesn't mean the medication is less effective for individuals; it just means we're now helping a broader group, including those with less severe versions of ADHD. It underscores the importance of careful diagnosis and tailored treatment for each patient.' Mental health professionals today recognize that many adults, including women, who would have been overlooked in the past now benefit from ADHD treatment. This broader inclusion is positive, as reductions in adverse outcomes such as self-harm, accidents, and criminal behavior are only part of the benefits of ADHD treatment. Dr. Sultan emphasized that the primary goal of ADHD treatment is to improve patients' daily functioning and quality of life, outcomes that are not always captured by statistics like accident or arrest rates. The new findings highlight the need to regularly re-evaluate prescribing practices and guidelines as the patient population evolves. Both the Swedish study and Dr. Sultan's commentary are slated for publication in JAMA Psychiatry. About Integrative Psych is a Manhattan-based mental health practice and research clinic led by Dr. Ryan Sultan, MD, who is an Assistant Professor of Clinical Psychiatry at Columbia University Irving Medical Center and the New York State Psychiatric Institute. Integrative Psych provides a holistic, evidence-based approach to ADHD and other psychiatric conditions, combining psychopharmacology, cognitive-behavioral therapy, ketamine-assisted treatment, mindfulness, and personalized care to improve everyday functioning and well-being. Dr. Sultan's team is dedicated to advancing outcomes through both clinical innovation and real-world effectiveness research. About Ryan S. Sultan, MD Ryan S. Sultan, MD, Director of Integrative Psychiatry, an Assistant Professor of Clinical Psychiatry at Columbia University Irving Medical Center and a Research Scientist at the New York State Psychiatric Institute. An internationally recognized expert in ADHD, he specializes in the diagnosis and treatment of ADHD across the lifespan and focuses his research on ADHD medication outcomes and public health. Social Links Instagram | Facebook | YouTube | LinkedIn Media Contact Full Name: Yiting Huang Title: Research Coordinator Company Name: Integrative Psych Email: [email protected] Phone Number: +1(551) 263-8239 Website:
